Case Report of Glanzmann Thrombasthenia

Unexplained Bleeding: Case Report of Glanzmann Thrombasthenia

Author: Ahmed Al Wahab1 , Alaa Nugud, M.D.2 , Shomous Nugud M.D.3, Zahran Alras1

Author Affiliations:

1College of Medicine, University of Sharjah, Sharjah, United Arab Emirates
2Department of Pediatrics, Dubai Health Authority, Dubai, United Arab Emirates
3Department of Research, Sharjah Institute for Medical Research, Sharjah, United Arab Emirates

[button link=”” type=”big” color=”green” newwindow=”yes”] Full Text Article PDF[/button]

Corresponding Author: Ahmed Al Wahab,

Key Words: Glanzmann Thrombasthenia, inherited platelet disorder, the disorder of hemostasis



Glanzmann Thrombasthenia (GT) is a rare inherited genetic platelet disorder characterized by a qualitative, or quantitative mutation in GPIIb/IIIa receptor; which results in defective platelet aggregation and diminished clot retraction.


A 19-year-old Arab descent female presented to emergency department with severe menorrhagia. On examination an ill looking pale patient in addition to generalized fatigue of one-week duration.


Acquired platelet disorders are more frequently encountered in practice than inherited ones, usually due to medical therapy or an underlying medical condition. GT, was previously known as hereditary hemorrhagic thrombasthenia, is an autosomal recessive disorder that is often disregarded as it has many clinical and laboratory findings similar to some acquired platelet disorders.

Published on date: September, 2017

DOI: 10.15404/msrj/09.2017.0127

Citation: Al Wahab, A., Nugud, A., Nugud, S., & Alras, Z. Unexplained Bleeding: Case Report of Glanzmann Thrombasthenia, Medical Student Research Journal (2017). doi:10.15404/msrj/09.2017.0127


  1. Stevens, R. & Meyer, S. (2002). Fanconi and Glanzmann: the men and their works. British Journal Of Haematology, 119(4), 901-904.
  2. Nurden, A., Ruan, J., Pasquet, J., Gauthier, B., Combrié, R., Kunicki, T., & Nurden, P. (2002). A novel 196 Leu to Pro substitution in the β3 subunit of the αIIbβ3 integrin in a patient with a variant form of Glanzmann thrombasthenia. Platelets, 13(2), 101-111.
  3. Solh, M., Solh, T., & Botsford, A. (2015). Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. Journal Of Blood Medicine, 219.
  4. Di Minno, G., Zotz, R., d’Oiron, R., Bindslev, N., Di Minno, M., & Poon, M. (2015). The international prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes in non-surgical bleeding episodes in Glanzmann thrombasthenia patients. Haematologica.
  5. iore, M., Nurden, A., Nurden, P., & Seligsohn, U. (2012). Clinical utility gene card for: Glanzmann thrombasthenia. European Journal Of Human Genetics, 20(10), 1102-1102.
  6. George, J., Caen, J., & Nurden, A. (1990). Glanzmann’s thrombasthenia: the spectrum of clinical disease. Blood, 75(7), 1383-1395.
  7. Seligsohn, U. (2003). Glanzmann thrombasthenia: a model disease which paved the way to powerful therapeutic agents. Pathophysiology Of Haemostasis And Thrombosis, 32(5-6), 216-217.